How have VCNX shares performed in 2023?

Vaccinex's stock was trading at $9.6675 at the beginning of 2023. Since then, VCNX shares have decreased by 91.5% and is now trading at $0.8201. View the best growth stocks for 2023 here .

Are investors shorting Vaccinex?

Vaccinex saw a increase in short interest in November. As of November 15th, there was short interest totaling 50,400 shares, an increase of 32.3% from the October 31st total of 38,100 shares. Based on an average daily volume of 631,200 shares, the short-interest ratio is currently 0.1 days. Approximately 0.8% of the company's shares are sold short. View Vaccinex's Short Interest .

When is Vaccinex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our VCNX earnings forecast .

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, November, 8th. The company reported ($2.55) earnings per share for the quarter, topping the consensus estimate of ($4.35) by $1.80. The firm had revenue of $0.05 million for the quarter.

When did Vaccinex's stock split?

Vaccinex's stock reverse split on Tuesday, September 26th 2023. The 1-15 reverse split was announced on Tuesday, September 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV) , OPKO Health (OPK) , Aldeyra Therapeutics (ALDX) , Sorrento Therapeutics (SRNE) , Cerecor (CERC) , Exelixis (EXEL) , Pfizer (PFE) , AVEO Pharmaceuticals (AVEO) , Heat Biologics (HTBX) and SCYNEXIS (SCYX) .

When did Vaccinex IPO?

(VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by a number of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (24.78%), Worth Venture Partners LLC (16.31%), Armistice Capital LLC (15.45%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert Friedberg, Jacob B Frieberg , Maurice Zauderer and Strydonck Gerald E Van. View institutional ownership trends .

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Vaccinex Stock Price, News & Analysis (NASDAQ:VCNX)

$0.82

-0.04 (-5.00%)

(As of 01:58 PM ET)

Compare

Today's Range: $0.77
▼
$0.87
50-Day Range: $0.82
▼
$2.39
52-Week Range: $0.77
▼
$12.36

Volume: 105,099 shs
Average Volume: 194,457 shs
Market Capitalization: $10.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Vaccinex MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.89
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$3 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vaccinex.

3.0

Short Interest

Percentage of Shares Shorted
0.79% of the float of Vaccinex has been sold short.
Short Interest Ratio / Days to Cover
Vaccinex has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vaccinex has recently increased by 32.28%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Vaccinex does not currently pay a dividend.
Dividend Growth
Vaccinex does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VCNX.

3.3

News and Social Media Coverage

News Sentiment
Vaccinex has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Vaccinex this week, compared to 0 articles on an average week.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaccinex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,004,650.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
55.90% of the stock of Vaccinex is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
50.11% of the stock of Vaccinex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Vaccinex is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaccinex is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaccinex has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vaccinex Stock (NASDAQ:VCNX)

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

VCNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VCNX Stock News Headlines

November 13, 2023 | finance.yahoo.com

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 31, 2023 | finance.yahoo.com

Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

October 26, 2023 | finance.yahoo.com

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

October 6, 2023 | markets.businessinsider.com

Why Is Vaccinex (VCNX) Stock Up 26% Today?

September 29, 2023 | finanznachrichten.de

Vaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public Offering

September 29, 2023 | marketwatch.com

Vaccinex Shares Slide Premarket After Stock Offering

September 29, 2023 | finance.yahoo.com

Vaccinex Announces Pricing of $9.6 Million Public Offering

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

September 28, 2023 | stockhouse.com

Vaccinex's Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration

September 28, 2023 | finance.yahoo.com

Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration

September 27, 2023 | finance.yahoo.com

Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application

September 26, 2023 | benzinga.com

Vaccinex Recent Insider Activity

September 22, 2023 | marketwatch.com

Vaccinex Board to Implement 1-for-15 Reverse Stock Split

September 22, 2023 | finance.yahoo.com

Vaccinex, Inc. Announces Reverse Stock Split

August 14, 2023 | finance.yahoo.com

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

June 1, 2023 | finance.yahoo.com

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET

May 31, 2023 | benzinga.com

Vaccinex Stock (NASDAQ:VCNX), Dividends

May 17, 2023 | seekingalpha.com

Vaccinex GAAP EPS of -$0.10, revenue of $0.55M

May 16, 2023 | finanznachrichten.de

Vaccinex, Inc.: Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

April 25, 2023 | finance.yahoo.com

Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab

April 12, 2023 | finance.yahoo.com

Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells

April 3, 2023 | finance.yahoo.com

Vaccinex Announces Private Placement with Commitments of $5.0 Million

April 3, 2023 | finance.yahoo.com

Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs

March 23, 2023 | finance.yahoo.com

Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference

March 21, 2023 | finance.yahoo.com

Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

March 9, 2023 | finance.yahoo.com

Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis

See More Headlines

Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/01/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VCNX
CUSIP: N/A
CIK: 1205922
Web: www.vaccinex.com
Phone: (585) 271-2700
Fax: 585-271-2765
Employees: 38
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($6.0376)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,820,000.00
Net Margins: N/A
Pretax Margin: -2,768.80%
Return on Equity: -2,667.31%
Return on Assets: -475.55%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 0.35
Quick Ratio: 0.35

Sales & Book Value

Annual Sales: $280,000.00
Price / Sales: 37.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.56 per share
Price / Book: 0.54

Miscellaneous

Outstanding Shares: 12,490,000
Free Float: 5,510,000
Market Cap: $10.62 million
Optionable: Not Optionable
Beta: 1.14

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Maurice Zauderer Ph.D. (Age 77)
Co-Founder, CEO, President & Director
Comp: $400.7k
Dr. Elizabeth E. Evans Ph.D. (Age 51)
COO and Senior VP of Discovery & Translational Medicine
Comp: $255.46k
Dr. Ernest S. Smith Ph.D. (Age 51)
Senior VP of Research & Chief Scientific Officer
Comp: $284.02k
Mr. Scott E. Royer C.F.A. (Age 49)
M.B.A., Chief Financial Officer
Comp: $242.15k
Dr. John E. Leonard Ph.D. (Age 76)
Senior Vice President of Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VCNX Stock Analysis - Frequently Asked Questions

How have VCNX shares performed in 2023?: Vaccinex's stock was trading at $9.6675 at the beginning of 2023. Since then, VCNX shares have decreased by 91.5% and is now trading at $0.8201.
View the best growth stocks for 2023 here.
Are investors shorting Vaccinex?: Vaccinex saw a increase in short interest in November. As of November 15th, there was short interest totaling 50,400 shares, an increase of 32.3% from the October 31st total of 38,100 shares. Based on an average daily volume of 631,200 shares, the short-interest ratio is currently 0.1 days. Approximately 0.8% of the company's shares are sold short.
View Vaccinex's Short Interest.
When is Vaccinex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our VCNX earnings forecast.
How were Vaccinex's earnings last quarter?: Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, November, 8th. The company reported ($2.55) earnings per share for the quarter, topping the consensus estimate of ($4.35) by $1.80. The firm had revenue of $0.05 million for the quarter.
When did Vaccinex's stock split?: Vaccinex's stock reverse split on Tuesday, September 26th 2023. The 1-15 reverse split was announced on Tuesday, September 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Vaccinex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).
When did Vaccinex IPO?: (VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.
Who are Vaccinex's major shareholders?: Vaccinex's stock is owned by a number of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (24.78%), Worth Venture Partners LLC (16.31%), Armistice Capital LLC (15.45%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert Friedberg, Jacob B Frieberg, Maurice Zauderer and Strydonck Gerald E Van.
View institutional ownership trends.
How do I buy shares of Vaccinex?: Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:VCNX) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial